Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cytokinetics, Incorporated (CYTK : NSDQ)
 
 • Company Description   
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.

Number of Employees: 253

 
 • Price / Volume Information   
Yesterday's Closing Price: $38.79 Daily Weekly Monthly
20 Day Moving Average: 1,056,023 shares
Shares Outstanding: 85.65 (millions)
Market Capitalization: $3,322.45 (millions)
Beta: 1.22
52 Week High: $47.90
52 Week Low: $17.72
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.98% 19.38%
12 Week 14.26% 25.62%
Year To Date -14.90% 3.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
350 OYSTER POINT BOULEVARD
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-624-3000
fax: 650-624-3010
investor@cytokinetics.com http://www.cytokinetics.com
 
 • General Corporate Information   
Officers
Robert I. Blum - President; Chief Executive Officer and Director
L. Patrick Gage - Chairman of the Board of Directors
Ching W. Jaw - Senior Vice President and Chief Financial Officer
Robert C. Wong - Vice President and Chief Accounting Officer
Santo J. Costa - Director

Peer Information
Cytokinetics, Incorporated (CORR.)
Cytokinetics, Incorporated (RSPI)
Cytokinetics, Incorporated (CGXP)
Cytokinetics, Incorporated (BGEN)
Cytokinetics, Incorporated (GTBP)
Cytokinetics, Incorporated (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 23282W605
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 85.65
Most Recent Split Date: 6.00 (0.17:1)
Beta: 1.22
Market Capitalization: $3,322.45 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.04 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.41 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 28.53
Price/Cash Flow: -
Price / Sales: 51.09
EPS Growth
vs. Year Ago Period: -54.55%
vs. Previous Quarter: -183.33%
Sales Growth
vs. Year Ago Period: -82.47%
vs. Previous Quarter: -97.94%
ROE
03/31/22 - -163.01
12/31/21 - -149.21
09/30/21 - -204.75
ROA
03/31/22 - -33.01
12/31/21 - -30.65
09/30/21 - -36.55
Current Ratio
03/31/22 - 9.33
12/31/21 - 7.45
09/30/21 - 6.12
Quick Ratio
03/31/22 - 9.33
12/31/21 - 7.45
09/30/21 - 6.12
Operating Margin
03/31/22 - -392.08
12/31/21 - -305.72
09/30/21 - -1,061.13
Net Margin
03/31/22 - -396.22
12/31/21 - -305.72
09/30/21 - -1,061.13
Pre-Tax Margin
03/31/22 - -396.22
12/31/21 - -305.72
09/30/21 - -1,061.13
Book Value
03/31/22 - 1.36
12/31/21 - 2.91
09/30/21 - 2.98
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 1.68
12/31/21 - 0.59
09/30/21 - 0.50
Debt-to-Capital
03/31/22 - 62.73
12/31/21 - 36.94
09/30/21 - 33.26
 

Powered by Zacks Investment Research ©